Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- MR Survey Shows Number of Doctors Visited, Detailing Activity Downtrend
March 14, 2012
- Pharmacists Rate Pfizer Highly for Generic Selection: Survey
March 14, 2012
- Nihon Chouzai to Provide Generic Drug Information System to Pharmacies of Other Companies
March 14, 2012
- Astellas and UMN Announce Favorable Phase II Results for Influenza HA Vaccine
March 14, 2012
- Sawai’s Next Midterm Management Plan Aims to Create a “Muscular Company”: Pres. Sawai
March 14, 2012
- MediciNova Obtains Notice of Patent Allowance for Ibudilast for Treatment of Chronic Neuropathic Pain
March 14, 2012
- Pfizer Reports 19% Boost in Sales in FY2011, “Continued Growth Possible” After Re-Pricing
March 13, 2012
- Upcoming Reforms “Ideal” for Promoting Use of Generic Drugs: President Sawai of Sawai Pharm.
March 13, 2012
- Nippon Shinyaku and Taiho to Cancel Licensing Agreement for Novel Antipruritic Agent
March 12, 2012
- UMN, IHI Start Construction of Biopharmaceutical Manufacturing Plant
March 12, 2012
- Novartis to Transfer Zaditen Ophthalmic Solution Marketing Rights to Alcon Japan
March 12, 2012
- Sosei Initiates PI Trial for Oropharyngeal Candidiasis Treatment SO-1105
March 12, 2012
- Taiyo to Discontinue Marketing Around 50 Products; Started Notifying Customers Last May
March 12, 2012
- Novo Nordisk Applies for Fixed-Dose Insulin Treatment
March 12, 2012
- Most Admired Pharma Companies in Japan
March 12, 2012
- Asahi Kasei to Acquire ZOLL Medical of the US for US$2.21 Bil.
March 12, 2012
- Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic While Patent Dispute Continues
March 12, 2012
- 5th Annual Marketing Excellence Japan 2012 – Hilton Tokyo, May 15 - 16
March 9, 2012
- 20 Companies Review Risk Countermeasures After Earthquake, Novartis Looks into MR Standards of Behavior: Jiho Survey
March 9, 2012
- Novartis Voluntarily Recalls 720,000 Diovan Tablets due to Insect Contamination
March 9, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…